|
1
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tucker MA: Melanoma epidemiology. Hematol
Oncol Clin North Am. 23:383–395. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated Melanoma. N Engl J Med. 373:23–34.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
D'Angelo SP, Larkin J, Sosman JA, Lebbé C,
Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al:
Efficacy and safety of nivolumab alone or in combination with
ipilimumab in patients with mucosal melanoma: A pooled analysis. J
Clin Oncol. 35:226–235. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ozaki Y, Shindoh J, Miura Y, Nakajima H,
Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, et al:
Serial pseudoprogression of metastatic malignant melanoma in a
patient treated with nivolumab: A case report. BMC Cancer.
17(778)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
López F, Rodrigo JP, Cardesa A,
Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan
P, Pellitteri PK, Bradford CR, et al: Update on primary head and
neck mucosal melanoma. Head Neck. 38:147–155. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D,
Ferrucci PF, et al: Overall Survival with Combined Nivolumab and
Ipilimumab in Advanced Melanoma. N Engl J Med. 377:1345–1356.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Huang AC, Postow MA, Orlowski RJ, Mick R,
Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell
invigoration to tumour burden ratio associated with anti-PD-1
response. Nature. 545:60–65. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Guisier F, Cousse S, Jeanvoine M,
Thiberville L and Salaun M: A rationale for surgical debulking to
improve anti-PD1 therapy outcome in non small cell lung cancer. Sci
Rep. 9(16902)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Joseph RW, Elassaiss-Schaap J, Kefford R,
Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C,
et al: Baseline tumor size is an independent prognostic factor for
overall survival in patients with melanoma treated with
pembrolizumab. Clin Cancer Res. 24:4960–4967. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu Y, Dong Y, Kong L, Shi F, Zhu H and Yu
J: Abscopal effect of radiotherapy combined with immune checkpoint
inhibitors. J Hematol Oncol. 11(104)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Oronsky B, Larson C, Reid TR and Carter
CA: Case series: Abscopal benefit of surgery in 3
immunotherapy-treated patients with unresectable cancer. J Investig
Med High Impact Case Rep: Jul 6, 2018 (Epub ahead of print). doi:
10.1177/2324709618786319.
|
|
16
|
Eggermont AMM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Prolonged survival in stage III melanoma with
ipilimumab adjuvant therapy. N Engl J Med. 375:1845–1855.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Weber J, Mandala M, Del Vecchio M, Gogas
HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V,
Marquez-Rodas I, et al: CheckMate 238 collaborators. Adjuvant
nivolumab versus ipilimumab in resected stage III or IV melanoma. N
Engl J Med. 377:1824–1835. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A,
Carlino MS, et al: adjuvant pembrolizumab versus placebo in
resected stage III melanoma. N Engl J Med. 378:1789–1801.
2018.PubMed/NCBI View Article : Google Scholar
|
